Edition:
United States

Genocea Biosciences Inc (GNCA.OQ)

GNCA.OQ on NASDAQ Stock Exchange Global Market

5.25USD
2:36pm EDT
Change (% chg)

$-0.01 (-0.19%)
Prev Close
$5.26
Open
$5.26
Day's High
$5.46
Day's Low
$5.25
Volume
22,854
Avg. Vol
102,592
52-wk High
$7.28
52-wk Low
$3.29

Latest Key Developments (Source: Significant Developments)

Genocea Biosciences reports qtrly loss per share $‍0.54​
Wednesday, 9 Aug 2017 08:00am EDT 

Aug 9 (Reuters) - Genocea Biosciences Inc :Genocea Biosciences reports second quarter 2017 financial results.Genocea Biosciences Inc - Qtrly loss per share $‍0.54​.Q2 earnings per share view $-0.47 -- Thomson Reuters I/B/E/S.Genocea Biosciences - ‍Expects existing cash, cash equivalents are sufficient to support operating expenses and capital expenditure requirements into 2018​.Genocea Biosciences Inc - ‍Is currently exploring various avenues to secure capital to advance GEN-003 into phase 3 trials​.Genocea Biosciences Inc - ‍Does not intend to commence phase 3 development of GEN-003 until it has secured such capital..  Full Article

Genocea reports positive top-line 12-month phase 2B data for GEN-003 in genital herpes
Monday, 24 Jul 2017 07:00am EDT 

July 24 (Reuters) - Genocea Biosciences Inc ::Genocea reports positive top-line 12-month phase 2b data for gen-003 in genital herpes.Genocea Biosciences Inc says statistically significant result on expected phase 3 primary endpoint with phase 3 dose.Genocea Biosciences Inc says in 131-subject phase 2B clinical trial, GEN-003 reduced median genital lesion rate versus placebo.Genocea Biosciences Inc says GEN-003 importantly, GEN-003 results were achieved at phase 3 dose and expected phase 3 primary endpoint.  Full Article

Genocea biosciences Q1 loss per share $0.48
Thursday, 4 May 2017 07:30am EDT 

May 4 (Reuters) - Genocea Biosciences Inc :Genocea reports first quarter 2017 financial results and positive clinical developments on lead candidate gen-003 in genital herpes.Q1 loss per share $0.48.Q1 earnings per share view $-0.54 -- Thomson Reuters I/B/E/S.Genocea-Expects existing cash, cash equivalents & investments are sufficient to support its operating exp, capex requirements & debt obligations into q1 2018.  Full Article

Genocea reports Q4 loss per share $0.56
Thursday, 16 Feb 2017 07:30am EST 

Genocea Biosciences Inc : Genocea reports fourth quarter and year-end 2016 financial results . Positive phase 2B clinical data confirm attractive profile for GEN-003; expected to start phase 3 program in 4Q 2017 . Neoantigen cancer vaccine program on track to file first IND by end of 2017 .Qtrly loss per share $0.56.  Full Article

Genocea qtrly loss per share $0.39
Thursday, 4 Aug 2016 07:30am EDT 

Genocea Biosciences Inc : Genocea reports second quarter 2016 financial results . Qtrly loss per share $0.39 .Expects that cash, cash equivalents to be sufficient to fund operating expenses, capex requirements into second half of 2017.  Full Article

Genocea Biosciences Inc announces top-line results from Phase 2a Trial for universal pneumococcal vaccine candidate GEN-004
Monday, 19 Oct 2015 07:00am EDT 

Genocea Biosciences Inc:Announces top-line results from Phase 2a Trial for universal pneumococcal vaccine candidate GEN-004.Says development suspended pending further review of data and potential paths forward.Says consistent reductions versus placebo in rate and density of colonization; not statistically significant.Says gen-004 was safe and well tolerated by subjects.Gen-004 reduced colonization rate, measured by microbiological culture, by between 22 and 25 percent versus placebo.Says there was no difference in the duration of colonization between gen-004 and placebo.Says none of the differences in study were statistically significant.For the time being, removing the development of gen-004 from our near-term plans.  Full Article